
SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (SNBL)

(TSE 1st section: 2395)

1Q FY2022

Supplementary Material on Quarterly Financial Results


August 4, 2021

Consolidated P/L

Quarterly Financial Results

(100 million of yen)

	FY2022/3	
	1Q results	Yoy
Net sales	30.4	-1.3
Operating Profit	4.9	+0.4
Ordinary Profit	6.7	-0.5
Profit Attributable to Owners of Parent	18.2	+11.8




Extraordinary income of **1.36 billion yen** due to a gain on change in equity relative to a subsidiary which engages in the business of laboratory animal breeding and raising in China.


Yoy Comparison of Consolidated Ordinary Profit & Loss: 1Q FY2022

	CRO business		Translational Research business	Medipolis business	Foreign exchange profit and loss	Other	Ordinary profit total
	Preclinical	Clinical (incl. PPD-SNBL)					
	1Q FY2022/3	6.6	1.9	-1.4	0.1	0.0	
1Q FY2021/3	6.2	3.5	-1.5	0.0	-0.7	-0.2	7.3
Yoy changes	+0.4	-1.6	+0.1	+0.1	+0.7	-0.2	-0.5

(100 million of yen)




Orders and Backlog of Preclinical CRO Business: 1Q FY2022




(100 million of yen)

Net sales




Operating Profit




(100 million of yen)

Ordinary Profit



Profit Attributable to Owners of Parent





Financial Data

(In millions of yen)	2017/3	2018/3	2019/3	2020/3	2021/3	2022/3 Forecasts
Sales	17,244	16,600	15,658	14,561	15,110	15,982
y/y change	16.9%	-3.7%	-5.7%	-7.0%	3.8%	5.8%
Operating profit	-1,792	-697	829	2,228	2,529	2,550
y/y change	—	—	—	168.5%	13.5%	0.8%
Equity method investment gains (losses)	12	637	361	888	846	
Ordinary profit	-2,105	-813	1,613	3,121	3,645	3,200
Net profit before income taxes	-764	-1,507	1,650	3,062	4,175	
Income taxes	127	2,013	-308	414	497	
Net profit attributable to owners of parent	-915	-3,555	1,950	2,550	3,661	3,900
EPS (yen)	-22.18	-85.41	46.84	61.25	87.95	93.67
Overseas sales	6,412	4,868	4,015	2,317	2,100	
Overseas sales ratio	37.2%	29.3%	25.6%	15.9%	13.9%	
Shareholders' equity	11,780	7,982	9,958	12,386	15,840	
Net assets	22,473	26,215	28,477	16,381	15,838	
Total assets	56,253	57,493	54,329	39,002	36,972	
Equity ratio	39.9%	45.5%	52.3%	41.8%	42.6%	
Capex	925	1,274	1,612	1,514	1,025	2,035
Depreciation & amortization	1,545	1,472	1,361	1,229	1,187	1,303
R&D expenses	600	518	339	400	392	742
R&D expenses to sales ratio	3.48%	3.12%	2.17%	2.75%	2.59%	4.64%
Year-end number of employees	1,506	1,385	935	985	986	
ROE	-4.7%	-14.6%	7.1%	11.4%	22.9%	
ROA	-4.0%	-1.4%	2.9%	6.7%	9.6%	
Operating profit to sales ratio	-10.4%	-4.2%	5.3%	15.3%	16.7%	16.0%
Dividend per share (yen)	—	—	3.0	5.0	20.0	20.0
DPR	—	—	6.4%	8.2%	22.7%	21.3%